Categorized: Abstracts & Presentations, Gastroenterology
Proton Pump Inhibitor Use in Patients with Helicobacter Gastritis is Associated with a High Prevalence of Corpus-Predominant Gastritis and Intestinal Metaplasia
European studies have shown that long-term proton-pump inhibitor (PPI) therapy in patients with GERD and antrum-predominant (AP) gastritis may induce a proximal shift of both bacteria and inflammation, resulting in corpus-predominant (CP) gastritis and acceleration of atrophy.
In the US it is unclear whether candidates for chronic PPI therapy are tested and treated for H. pylori infection. Thus, both the prevalence of chronic use of PPI in H. pylori-infected patients and the effects of this therapy are unknown.
This study was designed to test the hypothesis that the patterns of H. pylori gastritis are different in PPI users and non-users.
View the poster here.